Cough in Idiopathic Pulmonary Fibrosis.
Jennifer Mann, Nicole S L Goh, Anne E Holland and 1 others
PMID 36188759WHAT IT FOUND
Cough in idiopathic pulmonary fibrosis is common, distressing, and often underrecognized.
No therapy has proven effective in trials. Refractory cough may be referred to cough clinics for speech therapy or physiotherapy, but evidence is limited.
Key findings
01Cough is common in idiopathic pulmonary fibrosis, with up to 80% of patients experiencing chronic cough, and patients report physical and emotional distress that clinicians may not fully recognize.
02The review states that no therapy for cough in idiopathic pulmonary fibrosis has proved effective in clinical trials.
03For refractory cough, referral to specialized cough clinics for consideration of speech therapy, physiotherapy, or neuromodulation can be made, while evidence for speech therapy in this population is described as scarce.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a narrative review, not a primary clinical trial or systematic review, so it does not provide original evidence that a treatment works. The review states no therapy for cough in idiopathic pulmonary fibrosis has proved effective in clinical trials. Speech therapy and physiotherapy suggestions are drawn mainly from chronic cough research, and the review says evidence in idiopathic pulmonary fibrosis is scarce. Cough measurement tools discussed were developed for other chronic cough populations and are not fully validated in idiopathic pulmonary fibrosis. The relationship between cough and disease progression in idiopathic pulmonary fibrosis is not conclusively established.
Declared interests
YK reports grants and personal fees from Boehringer Ingelheim, personal fees from Roche, and other from Air Liquide Healthcare outside the submitted work. NG reports personal fees from Boehringer Ingelheim, Roche, AstraZenaca, and Novartis, and other from Air Liquide Healthcare outside the submitted work. AH reports non-financial support from BOC Ltd Australia and Air Liquide Healthcare outside the submitted work. The remaining author declares no commercial or financial relationships.
The easy way to misread this
Do not read the review's mention of speech therapy, physiotherapy, or neuromodulation as proof that any one of them reduces cough in idiopathic pulmonary fibrosis. The review states evidence in this population is scarce and that no therapy has proved effective in clinical trials.